CALGARY, Canada, December 21 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) has completed patient enrolment in its Phase Ia/Ib U.K. clinical trial investigating the intratumoural delivery of REOLYSIN(R) in combination with radiation to treat patients with advanced cancers. A total of 23 patients received a range of two to six intratumoural doses of REOLYSIN(R) at escalating dosages up to a maximum of 1x10(10) TCID(50) with a constant localized radiation dose of either 20 Gy or 36 Gy. The treatment appears to have been well tolerated by the patients and results in both local and remote anti-tumour activity in patients with a variety of advanced cancers.

ZUG, Switzerland, December 21 /PRNewswire/ -- AmVac AG has a new executive officer on board - Dr. Wolfgang Schmidt agreed to join the company in early December to lead its operational business.

DÜSSELDORF, Germany, December 21 /PRNewswire/ --

- Consistent Continuation of Globalisation Path and Extension of Product Offerings

Hydrogen is the fuel of the future. Unfortunately, one problem remains: Hydrogen is a gas and cannot easily be pumped into a tank like gasoline. Storage in the form of solid hydrides, chemical compounds of hydrogen and a metal or semimetal, are good storage materials in principle, but have not been well suited to automotive applications.

An American research team at the Ford Motor Company in Dearborn and the University of California, Los Angeles, has now developed a novel hydride that could be a useful starting point for the development of future automotive hydrogen-storage materials.

LONDON, December 21 /PRNewswire/ --

- Prenatal Omega 3 Supplementation has Long-Term Health Benefits for Unborn Babies

A new longitudinal study has shown that the benefits of prenatal omega 3 supplementation extend to the child's motor function in later life(1). The study, conducted in the Netherlands over 7 years, followed 300 children and related their motor abilities back to umbilical blood samples, which showed the levels of omega 3 essential fatty acid, Docosahexaenoic Acid (DHA) at the time of birth.

LONDON, December 21 /PRNewswire/ --

- Virgin Active Offers Healthy Advice on Joining Gyms in 2008

At a time when it is feared that mortgage debts are rising as quickly as obesity levels, Virgin Active has come up with suggestions to help people make an informed investment when joining a health club. The ideas that follow will enable individuals to remain financially sensible whilst trying to combat a tightening pinch around their waist lines as well as their wallets.

Top tips:

- Make sure that a sales representative fully explains the terms and conditions to you before you sign. If you don't have time, take the contract home and go through it at your leisure so you know what you are committing to.

Did you know even bacteria get old? Scientists traditionally assumed that bacteria were immortal, since these single-celled organisms split into two apparently identical daughter cells, which in turn divide, and so on. We now believe that this is not true. Eric Stewart of Northeastern University, and his colleagues took fluorescent images of individual E. coli cells over ten generations. Each generation the E. coli cells divide down the middle, giving each daughter cell one new tip and an old tip from its mother, or grandmother, or some older ancestor.

MELBOURNE, Australia, December 21 /PRNewswire/ --

Starpharma Holdings Limited (ASX:SPL, OTC: SPHRY), developer of VivaGel(R) vaginal microbicide today welcomed a decision by the US FDA this week requiring makers of products containing nonoxynol 9 (N9) to carry a warning that the products do not protect against sexually transmitted diseases, including HIV/AIDS and that the use of N-9 products is associated with an increased risk of HIV.

Starpharma's VivaGel(R) is a vaginal gel, being developed to protect women from HIV and HSV-2 (genital herpes) during sex. VivaGel(R) does not use N9. VivaGel(R) is currently in mid-stage clinical trials in the US and Kenya to add to its portfolio of safety data before embarking on population-based efficacy testing.

SAN MATEO, California, December 21 /PRNewswire/ -- Bizanga, the global company behind the most scalable and full-featured e-mail and message processing platform, today announced the appointment of Peter Zadrozny as Vice President of Product Management. A 25-year computer industry veteran, Zadrozny will guide the implementation of the company's product roadmap for its traditional carrier business as well as new ventures.

"Peter Zadrozny is a welcome addition to the Bizanga team," according to Marc Sheldon, Chief Marketing Officer for Bizanga. "His leadership and depth of experience will ensure the continued pre-eminence of Bizanga's platform as we build on our core technology to meet the evolving needs of carrier clients and move into new markets."

MALVERN, Pennsylvania, December 21 /PRNewswire/ --

Solstice Neurosciences, Inc. ("Solstice") announced the appointment of Dennis L. Smith as President and Chief Executive Officer. He will also continue to serve as Chairman to its Board of Directors.

Mr. Smith brings unique specialty pharmaceutical industry experience and expertise to Solstice that will be invaluable in providing guidance, leadership, and strategies for growth as the company continues to broaden its product portfolio globally and map its strategy.